scholarly journals A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry

2014 ◽  
Vol 89 (3) ◽  
pp. 343-344
Author(s):  
Federica Capolunghi ◽  
Claudia Capponi ◽  
Barbara De Stefani ◽  
Matteo Luciani ◽  
Franco Locatelli ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Acute Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Childhood Acute Myeloid Leukemia ◽  
Minimal Residual ◽  
Acute Myeloid

scholarly journals Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

Cancer ◽  
2013 ◽  
Vol 119 (22) ◽  
pp. 4036-4043 ◽  
Author(s):  
Carol O'Hear ◽  
Hiroto Inaba ◽  
Stanley Pounds ◽  
Lei Shi ◽  
Gary Dahl ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Gemtuzumab Ozogamicin ◽  
Childhood Acute Myeloid Leukemia ◽  
Minimal Residual ◽  
Acute Myeloid

scholarly journals Detection of minimal residual disease in adult acute myeloid leukemia via CD25

2019 ◽  
Author(s):  
Wei Wang ◽  
Yan Li ◽  
Lan Ma ◽  
Wen-Qing Hu ◽  
Bin Jiang
Keyword(s):  
Flow Cytometry ◽  
Acute Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Detection Sensitivity ◽  
Cell Subpopulation ◽  
The Mean ◽  
Minimal Residual ◽  
Acute Myeloid

Abstract Background We detected the expression of CD25 in patients with acute myeloid leukemia (AML) to value whether CD25 could be a promising marker for minimal residual disease (MRD). Methods Two hundred and twenty bone marrow (BM) specimens from 98 adult patients with AML after chemotherapy were detected using flow cytometry. The expression of CD25 was compared between MRD positive and negative subgroups. Results About 38% of patients with MRD were positive for CD25. The mean percentage of CD25-positive cell subpopulation was 58.68% relative to the whole MRD cluster (0.05%-100%). The mean fluorescence index ratio (MFIR) of CD25 in these cell subpopulations was approximately13-fold greater than that in normal myeloblasts. The detection sensitivity of CD25 was as high as 10 -4 . CD25 was also expressed on non-leukemic stem cells that were positive for CD34 and CD38. Conclusion CD25, as assessed by flow cytometry, is a promising marker for MRD in patients with AML.

Sign in / Sign up

Export Citation Format

Share Document